openPR Logo
Press release

Peyronie’s Disease Treatment Market

06-27-2017 12:59 PM CET | Health & Medicine

Press release from: Pharmaceutical

Peyronie's disease (PD) is condition wherein the penis is curved or bent due to development of plaque or a fibrous scar tissue inside the penis. This condition can cause painful erections and the penis gets bent while it is erected. The bent is towards the side where plaque is being formed i.e. either downwards or upwards. The condition is identified by a major bend or pain. In a few people Peyronie's disease may go away on its own. However, in most cases it may remain stable or worsen. Hence, it is advisable to visit an urologist to avoid consequences in future. Treatment may be needed if the curvature prevents successful sexual intercourse.

Peyronie’s disease is a rare condition observed in about 6 out of 100 men in the age group of 40 to 70 years. Moreover, the Urology Care Foundation also estimates that the number of people affected by this condition can be higher than this as many men are embarrassed and do not see their healthcare provider. It is mostly at times when the men visit the healthcare practitioner for erectile dysfunction treatment and the healthcare practitioner may notice Peyronie’s disease. Lack of awareness among patients has resulted in under reporting of this condition.

Request a sample copy of this report@
https://www.coherentmarketinsights.com/insight/request-sample/61

Peyronie's Disease Treatment Options

The exact cause of plaque formation is not known. Hence, treatment is done with the available research and knowledge of plaque formation. There are various treatment options followed for Peyronie’ disease basis on which the market is analyzed. These include drugs, surgery and devices. The drugs market can be analyzed based on the administration route i.e. oral and injectable. Drugs prescribe through oral route include Vitamin E, Potassium amino-benzoate ("Potaba"), Tamoxifen, Colchicine, and Carnitine. Similarly, the injectable drugs include Verapamil, Interferon, and Collagenase. Use of oral drugs is limited as none of the studies conducted so far for Peyroniee’s disease have shown positive results of these drugs over the placebo.

On the other hand injectables show some positive outcomes over placebo. However, more studies are required to establish the efficacy. Studies with collagenase have shown positive outcomes for its use in Peyronie's disease. Therefore, Xiaflex (Collagenase clostridium histolyticum) from BioSpecifics Technologies Corporation is the only FDA approved product indicated for Peyronie's disease in adult men. Approved in 2013, Xiaflex is marketed in the U.S. by Endo International plc. In Europe, Collagenase clostridium histolyticum is available by the brand name Xiapex.

A penile prosthetic device is another good treatment option for Peyronie's disease and moderate-to-severe ED. This device helps straighten the penis. Surgical procedure on the other hand involves grafting the space being emptied on removal of the plaque.

With Xiaflex the only FDA approved product for this disease, Endo dominates the market

The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product is estimated to generate USD 100 million in revenue for Peyronie’s disease by 2018. In Japan, BioSpecifics Technologies Corp. has granted Asahi Kasei Pharma the rights to develop and market XIAFLEX in Japan for Peyronie's disease. Further, the company is also partnering with global companies in Canada, Europe, Mexico, and Brazil for commercializing XIAFLEX for PD.

With increasing awareness and research on this disease, new drug molecules could be made available in the market.

Get More Details about this Report@
https://www.coherentmarketinsights.com/ongoing-insight/peyronies-disease-treatment-market-61

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit Coherent Market Insights Blog @ https://blog.coherentmarketinsights.com
Connect with us on LinkedIn @ https://www.linkedin.com/company/coherent-market-insights

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Peyronie’s Disease Treatment Market here

News-ID: 597259 • Views: 361

More Releases from Pharmaceutical

Pharmaceutical Market Report 2018 Companies included CCM Pharmaceuticals, Pharma …
We have recently published this report and it is available for immediate purchase. For inquiry Email us on: jasonsmith@marketreportscompany.com ********* This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to 2025, etc. The report also provides
Equine Healthcare Market Global Industry Insights, Trends, 2026
Equine Healthcare refers to the activities and practices aimed for the maintenance of horses. Equine healthcare offers the veterinary services intended for treating horses to enhance their quality of life, develop quality animal food and increase lifespan. The total equine population is directly proportional to the quality of equine healthcare. Equine healthcare includes a number of activities including diagnosis, therapies and supplements for maintaining internal health of horses. The
Novel Drug Delivery System (NDDS) Market - Global Industry Insights
Novel Drug Delivery System (NDDS) refers to the formulations, systems to transport pharmaceutical compound in the body, and approaches needed to achieve the desired therapeutic effect. The side effects and slow processing of conventional drug therapy are contributing to the emergence of novel drug delivery system’s concept. Novel ideas based on interdisciplinary approaches controlling the pharmacodynamics, immunogenicity, pharmacokinetics, bio-recognition, and efficiency of drugs were generated. This new system helps in
The Global Anti-suicide Drugs Market was valued at US$ 3,318.3 million in 2015 a …
The Global Anti-suicide Drugs Market was valued at US$ 3,318.3 million in 2015 and is projected to expand at a CAGR of 4.2% during the forecast period (2016-2024), as highlighted in a new report published by Coherent Market Insights. Introduction of novel approved drugs, expected to be commercialized post-2020, intended for treatment of suicidal ideation would be a major breakthrough for the global anti-suicide drugs market. Until recently, suicidal ideation has

All 5 Releases


More Releases for Peyronie

Peyronie’s Disease Treatment Market Set to Encounter Paramount Growth
The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product
Peyronie’s Disease Market Growing Popularity and Emerging Trend by 2026
The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product
Peyronie’s Disease Treatment Market Is Likely to Witness Tremendous Growth by …
The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product
Peyronie’s Disease Market - Only FDA approved product
The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product
With Xiaflex the only FDA approved product for this disease, Endo dominates the …
The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product
Peyronie’s Disease Treatment Market to Rear Excessive Growth With Key Players …
A penile prosthetic device is another good treatment option for Peyronie's disease and moderate-to-severe ED. This device helps straighten the penis. Surgical procedure on the other hand involves grafting the space being emptied on removal of the plaque. "With Xiaflex the only FDA approved product for this disease, Endo dominates the market" The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product.